(pipeline)
A portfolio of pharmaceutical assets under construction.
Aether identifies, selects, and develops pharmaceutical assets with value-creation potential throughout their maturation journey. As a Pharmaceutical Asset Venture Builder, we build a portfolio guided by science, intellectual property, and progressive development milestones, focused on reducing risk and creating value up to partnership, investment, or licensing opportunities.
(featured project)
Selected in a R$90 million national public call.
Aether Global Pharma is part of the High-Impact Health Projects, an initiative by Brazil's Ministry of Health and EMBRAPII, developing a production platform for an anti-inflammatory API in partnership with CQMED and UFMG's Drug Innovation unit.
Production platform for an anti-inflammatory API.
(how we organize)
Three dimensions for reading each project.
Aether's pipeline is translational by nature. As it grows, each asset is presented through three axes that make its development stage comparable.
Asset Maturity
Where the asset stands in its development journey. The technology readiness level shows the project's current stage, the evidence already built, and the next milestones needed for its advancement.
Value Thesis
Why this asset deserves to advance. Each project is analyzed based on its scientific rationale, therapeutic potential, intellectual property strategy, and capacity to generate value throughout development.
Next Value-Creation Milestone
What needs to happen to increase the asset's value. We identify the next milestone capable of reducing risk, strengthening evidence, and expanding the asset's potential for investment, strategic partnership, or licensing.
(expanding)
A pipeline taking shape.
Starting in 2027, new assets will join the pipeline at different maturity stages. Some projects remain confidential until cleared for disclosure, and will be detailed here as they progress.